Compare Stocks

Enter up to five stock symbols separated by a comma or space (ex. BAC,WFC,JPM,LON:BARC).

Date Range:

	AgeX Therapeutics	Salarius Pharmaceuticals	Rezolute	Appili Therapeutics	Evoke Pharma
Symbol	NYSE:AGE	NASDAQ:SLRX	NASDAQ:RZLT	OTCMKTS:APLIF	NASDAQ:EVOK
Price Information
Current Price	$1.33	$1.20	N/A	$1.03	$1.55
52 Week Range	N/A	Buy	Buy	Buy	Buy
MarketRank™
Overall Score	0.5	1.5	0.6	1.7	1.4
Analysis Score	0.0	3.5	0.0	3.5	3.5
Community Score	2.4	2.7	2.8	5.0	3.0
Dividend Score	0.0	0.0	0.0	0.0	0.0
Ownership Score	0.0	0.0	0.0	0.0	0.0
Earnings & Valuation Score	0.0	1.3	0.0	0.0	0.6
Analyst Ratings
Consensus Recommendation	N/A	Buy	Buy	Buy	Buy
Consensus Price Target	N/A	$5.00	$30.00	$2.50	$10.00
% Upside from Price Target	N/A	316.67% upside	∞ upside	143.55% upside	545.16% upside
Trade Information
Market Cap	$50.45 million	$53.68 million	$58.46 million	$64.44 million	$50.18 million
Beta	1.5	2.01	3.97	N/A	1.41
Average Volume	311,021	2,215,525	12,816	66,628	669,379
Sales & Book Value
Annual Revenue	$1.73 million	$3.46 million	N/A	$150,000.00	N/A
Price / Sales	29.16	15.51	N/A	429.60	N/A
Cashflow	N/A	N/A	N/A	N/A	N/A
Price / Cash	N/A	N/A	N/A	N/A	N/A
Book Value	$0.07 per share	$2.35 per share	$1.26 per share	N/A	$0.18 per share
Price / Book	19.00	0.51	N/A	∞	N/A
Profitability
Net Income	$-12,150,000.00	$-6,940,000.00	$-20,330,000.00	$-4,070,000.00	$-7,130,000.00
EPS	N/A	($2.12)	N/A	N/A	($0.32)
Trailing P/E Ratio	N/A	N/A	0.00	N/A	N/A
Forward P/E Ratio	∞	N/A	N/A	∞	N/A
P/E Growth	N/A	N/A	N/A	N/A	N/A
Net Margins	-582.11%	-155.82%	N/A	N/A	N/A
Return on Equity (ROE)	-932.89%	-45.22%	-205.36%	-56.50%	-983.14%
Return on Assets (ROA)	-207.13%	-39.52%	-140.74%	-47.10%	-188.91%
Dividend
Annual Payout	N/A	N/A	N/A	N/A	N/A
Dividend Yield	N/A	N/A	N/A	N/A	N/A
Three-Year Dividend Growth	N/A	N/A	N/A	N/A	N/A
Payout Ratio	N/A	N/A	N/A	N/A	N/A
Years of Consecutive Dividend Growth	N/A	N/A	N/A	N/A	N/A
Debt
Debt-to-Equity Ratio	N/A	N/A	N/A	0.05%	N/A
Current Ratio	0.40%	5.66%	2.36%	13.74%	1.01%
Quick Ratio	0.40%	5.67%	2.36%	13.74%	1.00%
Ownership Information
Institutional Ownership Percentage	13.17%	3.77%	N/A	N/A	7.06%
Insider Ownership Percentage	3.33%	4.10%	4.60%	N/A	10.27%
Miscellaneous
Employees	6	7	23	N/A	5
Shares Outstanding	37.94 million	44.73 million	8.35 million	62.78 million	32.37 million
Next Earnings Date	5/13/2021 (Estimated)	5/13/2021 (Estimated)	5/12/2021 (Estimated)	6/23/2021 (Estimated)	5/11/2021 (Estimated)
Optionable	Not Optionable	Not Optionable	Not Optionable	Not Optionable	Not Optionable

Source	Headline
	Evoke Pharma to Report First Quarter 2021 Financial Results on May 12, 2021 finance.yahoo.com - May 5 at 1:43 PM
	Evoke Pharma, Inc. (NASDAQ:EVOK) is an exciting stock to watch stocksregister.com - May 1 at 1:49 PM
	Evoke Pharma (NASDAQ:EVOK) Stock Crosses Below Two Hundred Day Moving Average of $2.90 americanbankingnews.com - May 1 at 3:38 AM
	Evoke Pharma, Inc. (NASDAQ:EVOK) Currently 267.46% Below Its 52-week High But The Upside Potential May Surprise You marketingsentinel.com - April 18 at 7:00 AM
	Short Interest in Evoke Pharma, Inc. (NASDAQ:EVOK) Grows By 46.7% americanbankingnews.com - April 17 at 1:01 PM
	Analysts Expect Breakeven For Evoke Pharma, Inc. (NASDAQ:EVOK) Before Long nasdaq.com - April 16 at 7:35 AM
	Forced Into A Patient Advocate Role? Trust Your Business Skills forbes.com - April 11 at 12:28 AM
	CoronaVac? BBIBP-CorV? Sputnik? Meet the world’s three other COVID-19 vaccines thestar.com - April 11 at 12:28 AM
	Evoke Pharma’s Gimoti nasal spray for treatment of gastroparesis receives US patent pharmabiz.com - April 8 at 5:24 AM
	Evoke Pharma Receives Notice of Allowance from United States Patent and Trademark Office for a ... apnews.com - April 6 at 7:47 PM
	Evoke Pharma Receives Notice of Allowance from United States Patent and Trademark Office for a Method of Use Patent with Claims Covering Gimoti® finance.yahoo.com - April 6 at 9:17 AM
	Evoke Pharma Announces a Fireside Chat with Key Opinion Leaders on the Treatment of Gastroparesis finance.yahoo.com - March 30 at 12:38 PM
	Wall Street’s take on Evoke Pharma, Inc. (NASDAQ:EVOK) stock stocksregister.com - March 27 at 1:11 PM
	Evoke Pharma, Inc. (NASDAQ:EVOK) Is Expected To Breakeven In The Near Future finance.yahoo.com - March 14 at 2:08 PM
	Evoke Pharma Reports Fourth Quarter and Full Year 2020 Financial Results finance.yahoo.com - March 11 at 7:50 PM
	Evoke Pharma, Inc. (EVOK) Reports Q4 Loss, Misses Revenue Estimates finance.yahoo.com - March 11 at 7:50 PM
	Evoke Pharma, Inc. to Host Earnings Call finance.yahoo.com - March 11 at 2:50 PM
	Evoke Pharma to Report Fourth Quarter and Full Year 2020 Financial Results on March 11, 2021 finance.yahoo.com - March 4 at 6:37 PM
	Global Treatment for Gastroparesis Market 2020 Opportunity Assessment, Key Drivers and Challenges, Growth Rate and Forecast to 2025 marketwatch.com - March 1 at 10:34 PM
	The Escalator: Syneos Health Communications appoints six senior specialists mmm-online.com - February 26 at 10:07 AM
	Stock Alert: Evoke Pharma Gains 30% nasdaq.com - February 9 at 3:20 PM
	Evoke Pharma Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriter's Option to Purchase Additional Shares stockhouse.com - January 21 at 7:09 PM
	Evoke Pharma Announces Closing of Public Offering of Common Stock and Full Exercise of ... apnews.com - January 20 at 5:41 PM
	Evoke Pharma Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriter’s Option to Purchase Additional Shares finance.yahoo.com - January 20 at 5:41 PM
	EVOK Feb 2021 5.000 call uk.finance.yahoo.com - January 17 at 9:27 PM

Date	Company	Brokerage	Action
6/16/2020	Salarius Pharmaceuticals	Benchmark	Initiated Coverage
4/27/2020	Salarius Pharmaceuticals	LADENBURG THALM/SH SH	Initiated Coverage
10/14/2020	Rezolute	JMP Securities	Boost Price Target
9/9/2019	Rezolute	Canaccord Genuity	Initiated Coverage
1/29/2021	Appili Therapeutics	Maxim Group	Reiterated Rating
8/10/2020	Evoke Pharma	HC Wainwright	Reiterated Rating
3/4/2019	Evoke Pharma	B. Riley	Set Price Target

(Data available from 5/6/2018 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Comparison Ideas:

30 Days of MarketBeat All Access for $1.00

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here

Your Ultimate Investing Toolkit

Just $1.00 for your first month.

Compare Stocks

30 Days of MarketBeat All Access for $1.00

Resources

Premium Research Tools

Market Data and Calendars

Investing Education and Resources